DRIVIN G ROWTH - Dr. Reddy's

52
management discussion
and analysis
launch of new products such as gatifloxacin
and clopidogrel sesquihydrate in the
domestic market, coupled with
increase in sales of nizatidine,
ciprofloxacin and ranitidine in
the international markets.
During the year, the Company
filed 8 drug master files (DMFs)
in the US, taking the total to 26,
as well as 34 dossiers in Europe. Table 3
gives the sale of the top APIs and their
share in total APIs revenues.
As far as international revenue of APIs is
concerned, Dr. Reddy’s supplies to the
world’s largest generic players. With the
anticipated growth in the global generics
business after 2005 — when a large number
of formulations go off-patent — the
Company’s APIs business should see
significant growth.
BRANDED FORMULATIONS
THE BRANDED FORMULATION
business recorded a 23 per cent increase
— in revenue to Rs. 6,057 million in 2001-
02, compared to Rs. 4,938 million during the
previous year. International revenue grew
by 55 per cent, driven by a 100 per cent
increase in sales to Russia. Revenue from
the Indian market grew by 11 per cent,
primarily due to performance of top brands
such as Nise, Stamlo and Omez, as well as
19 new brand launches which accounted
for 50 per cent of the total growth. Some of
the new brands were Gaity, Clamp, Ebiza,
Plagril, Fiona and Zubair. Sale of the dental
brands acquired from Group
Pharmaceuticals commenced in the fourth
quarter of 2001-02, and contributed Rs. 23
million to Indian revenue.
According to ORG, Dr. Reddy’s is ranked
Table 4
|
India Top-10 brands
RS. MILLION
2001-02 AS A % 2000-01 AS A %
Nise 588 14.5% 445 14.5%
Omez 463 11.5% 440 11.5%
Stamlo 244 6.0% 233 6.0%
Ciprolet 219 5.4% 275 5.4%
Enam 143 3.5% 146 3.5%
Stamlo Beta 129 3.2% 110 3.2%
Antoxid 110 2.7% 97 2.7%
BIO E 87 2.2% 90 2.2%
Reclide 53 1.3% 59 1.3%
GLA 96 2.4% 92 2.4%
Others 1,910 47.2% 1,655 47.2%
Total 4,042 100.0% 3,642 100.0%
DR. REDDY’S LABORATORIES LTD. | MANAGEMENT DISCUSSION AND ANALYSIS | ANNUAL REPORT 2001-2002